Five strategic paths to scale a medical infusion services company from zero to a $1B exit — and the one that actually wins.
Every year in the United States, over $80 billion in biologic drugs are administered to patients managing chronic autoimmune, neurological, and immunological conditions. The infrastructure delivering those drugs is fragmented, hospital-dominated, and overpriced. There is no dominant national brand. That is the opportunity.
The legacy infusion industry was built around hospitals and academic medical centers. Hospital outpatient infusions cost Medicare and private insurers 40–60% more than free-standing infusion centers for identical medications. As payers aggressively shift volume away from hospital settings to lower-cost sites of service, an enormous transfer of revenue is currently underway. Whoever builds the modern, tech-enabled, geographically dense alternative captures it.
The model that wins looks nothing like Restore Hyper Wellness, The DRIPBaR, or Drip Hydration. It is closer to Option Care Health (NASDAQ: OPCH, $5B+ market cap), InfuCare Rx, or Coram CVS: insurance-reimbursed, physician-supervised, biologic-focused, geographically dense. But none of those companies has built a defensible digital moat. That is the white space.
Five tailwinds are compressing the existing infusion market into the lane you’re building in.
Site-of-service shifting. Payers — Medicare, BCBS, UnitedHealthcare — have spent the last five years actively steering patients away from hospital outpatient infusion suites. CMS has issued multiple rule changes reducing hospital reimbursement for the same J-codes paid in free-standing centers. This is an active, ongoing, multi-year transfer of revenue.
Pipeline acceleration. FDA approved 55 new biologics in 2024 alone, and the pipeline of monoclonal antibodies, gene therapies, and biosimilars projected through 2030 is the largest in pharmaceutical history. Every new biologic creates new infusion volume. None of it goes to your competitors at Drip Hydration.
Aging population. The US population aged 65+ will grow from 58 million to 73 million between 2022 and 2030. This is the patient population that consumes the highest volume of biologic infusions — for rheumatoid arthritis, osteoporosis, lupus, multiple sclerosis. Medicare Part B is the largest payer of biologics in the country.
Specialist consolidation. Rheumatology, neurology, and gastroenterology practices are being aggressively rolled up by private equity. These consolidated practices want a dedicated infusion partner — not a hospital with three-week wait times. They want one number to call, one referral process, one accountable partner.
Tech debt in the existing players. Option Care, BioScrip, and Coram are operationally strong but technologically frozen. Their patient acquisition is referral-only. Their prior auth is manual. Their patient experience is utilitarian. They cannot move quickly enough to defend against a tech-native challenger.
“Build the Option Care Health of the 2030s — but vertically integrated with technology, not just operations.”
This is the foundational play. You operate free-standing, accredited infusion centers that administer biologic therapies prescribed by referring specialists. Revenue is generated through three primary streams: drug margin (typically Medicare ASP + 6% for Part B drugs, higher for private payers), administration fees (J-codes ranging $150–$450 per session), and ancillary services (office visits, lab draws, supportive medications).
Patient lifetime value is enormous. A patient with rheumatoid arthritis on Remicade receives 6–8 infusions per year, often for 10+ years. Average reimbursement per infusion: $3,000–$6,500 depending on payer and drug. Lifetime value per patient: $200,000–$500,000. A center running at 2,500 active patients generates $30–60M in annual revenue.
| Unit Economics — Mature Single Clinic | Year 1 | Year 3 Mature |
|---|---|---|
| Active patients | 350–500 | 2,000–2,500 |
| Annual infusion volume | 2,800–4,000 | 14,000–18,000 |
| Gross revenue | $4–7M | $28–45M |
| EBITDA margin | 5–10% | 22–28% |
| Mature EBITDA per clinic | $200K–700K | $6–12M |
“The Medvi insight, applied with technical depth. Own the operational nervous system every infusion center needs but cannot build for itself.”
Every infusion center in America loses money on two specific problems: prior authorization (manual, slow, error-prone, denies up to 30% of cases) and patient acquisition (referral-dependent, no digital channel). An AI-powered platform that solves both problems becomes infrastructure — not a service.
This is the Medvi pattern translated into infrastructure tech. Medvi reached a $1.8B valuation by owning the digital funnel for a regulated category. You build the same digital funnel for infusion patients, plus an AI prior auth engine that processes denials and resubmissions in minutes instead of days. Then you license the platform to existing infusion centers nationally while operating your own as the proof point.
This is the highest-multiple business in the strategy. SaaS infrastructure in healthcare trades at 10–20× ARR. A $50M ARR platform conservatively reaches a $500M–$1B valuation. The same revenue from clinic operations would require 7–10× the operational complexity.
“The same patient generates revenue from the pharmacy buying the drug, the clinic administering it, and the billing operation collecting from insurance. Capture all three.”
The largest infusion businesses in America — Option Care, CVS Coram, Walgreens AllianceRx — are vertically integrated. They own both the specialty pharmacy that procures and compounds the biologics, and the infusion center that administers them. This is not a coincidence. The drug margin alone is 6–15% of cost, and on a $30,000 dose of Ocrevus, that is a $1,800–$4,500 spread per administration.
The play: license a specialty pharmacy (or acquire a small one), use it to supply your infusion centers, and over time, supply other independent centers as well. This dramatically improves your margin profile, gives you control over drug supply (critical during shortages like the Baxter IV bag disruption of 2024), and creates additional B2B revenue streams.
“Walmart, Amazon, JPMorgan, and General Motors pay billions per year for their employees’ specialty infusions through their self-funded health plans. Show them you can deliver the same drugs at 40–60% lower cost than the hospital outpatient setting. The check that follows is enormous.”
Self-insured employers — companies that pay their own healthcare claims rather than buying insurance — collectively account for 65% of all US workers covered by employer plans. Their CFOs and benefits leaders are aggressively hunting for site-of-service savings on specialty drugs. A single biologic infusion administered at a hospital outpatient setting costs the employer $8,000–$18,000. The same infusion at a free-standing center costs $3,500–$7,000. The math sells itself.
This play opens a different sales motion entirely — enterprise B2B, multi-year contracts, large account management. Average contract value: $500K–$5M per year per employer. Customer concentration risk is real but so is contract durability. Five major contracts could underwrite a 50-location national footprint.
“The infusion industry has over 1,000 independent free-standing centers, most owned by single physicians or small groups. Most are operationally lean, undermarketed, and ready to exit. This is the same playbook PE used in dermatology, dental, and physical therapy.”
The infusion market is the textbook PE roll-up target: highly fragmented, healthy unit economics, recurring revenue, demographic tailwinds, and a sellable end-state. Independent infusion centers typically trade at 5–7× EBITDA at acquisition. A roll-up that consolidates 30+ centers can achieve scale multiples of 12–15× at exit. This is pure financial engineering combined with operational improvement.
The capital-intensive nature of this play makes it best suited to KVLR Capital as the platform sponsor, with institutional debt and equity raised in stages. The strategic value is not just the rolled-up EBITDA but the network effect: as the network gets larger, payer contracting leverage grows, drug procurement costs drop through scale, and corporate overhead spreads across more revenue.
“Operate one elite infusion center in a major metro. Use it as the proof point for a software platform you sell to every other infusion center in America. Years later, vertically integrate by acquiring a specialty pharmacy. This is the same architecture that built Toast in restaurants and Veeva Systems in life sciences.”
The single play that wins is the one with the strongest defensibility and the highest multiple. Plays 1 and 2 reinforce each other. Operating the clinic gives you proprietary operational data, real workflows, and credibility with future enterprise customers. Building the software platform turns every learning from clinic operations into a defensible product asset that scales without proportional capital.
The clinic generates predictable EBITDA at healthcare services multiples (8–12×). The software platform generates ARR at SaaS multiples (10–20×). At scale, the software business is the larger valuation driver. But the clinic is what makes the software trustworthy — and the data flywheel from the clinic is what makes the software AI actually work.
Play 3 (vertical pharmacy integration) gets added in Year 3 once cash flow supports the regulatory and capital lift. Play 4 (self-insured employers) becomes the enterprise sales motion in Year 4. Play 5 (roll-up) is the optionality at exit — you can either be acquired by a strategic, IPO independently, or use proceeds to consolidate.
This is the architecture that compounds. Every clinic you operate makes the software better. Every software customer makes the clinics more efficient. Vertical pharmacy integration captures additional margin from both. Self-insured employer contracts give you the demand pipeline. The roll-up becomes the late-stage M&A toolkit.
Open one accredited infusion center in your launch metro. Hire a medical director, two infusion RNs, a billing manager, and a referral liaison. Begin building the AI prior auth product in parallel with a small founding engineering team (2–3 engineers, 1 clinical informaticist). Establish referring physician relationships with 15–20 specialists in rheumatology, neurology, and gastroenterology.
Open centers two and three in adjacent metros. The first center reaches 60% mature patient volume. Software platform goes live with 5 design partner infusion centers (non-competing). Prior auth approval rates demonstrably improve by 12–18% in beta customers. Begin courting payer contracting for direct in-network status. Raise Series A of $20–35M.
Centers four through ten open in a coordinated geographic strategy. AI prior auth platform crosses $5M ARR with 30+ paying customers. Vertical integration step: acquire a regional specialty pharmacy ($15–25M acquisition). Begin direct payer contracts with two major plans. Launch first enterprise contracts with self-insured employers. Raise Series B of $50–80M.
Geographic expansion accelerates with proven operational playbook. Centers 11–25 open across major metros. Enterprise self-insured employer channel becomes a meaningful revenue contributor with 8–12 large contracts ($30M+ ARR from this channel alone). Software platform reaches $20M ARR. Begin selective M&A of single-location independent centers. Hire institutional CFO and General Counsel.
40+ centers operational. Software platform at $40M+ ARR with 200+ infusion center customers. Vertical pharmacy supplying internal and external clinics. Three viable exit paths actively considered: (1) strategic acquisition by Option Care, CVS, Walgreens, or a managed care organization; (2) IPO with sufficient revenue and EBITDA to support a $1.5–2B public market valuation; (3) PE recap allowing partial liquidity with continued growth.
Every billion-dollar company is built on a compounding moat. Five compound in this strategy.
Every infusion in your clinics generates structured data — prior auth outcomes, denial reasons, payer behavior. This trains your AI better than any competitor without operational depth.
Direct in-network status with major payers is a multi-year process. Once you have it across 25 centers, you cannot be displaced quickly.
An infusion center that runs its prior auth, intake, scheduling, and billing on your platform cannot rip and replace without crippling its operations.
Specialists who develop trust with your local centers continue referring for years. Once entrenched in a regional referral pattern, you are the default.
Vertically integrated drug procurement at scale produces a 4–8% cost advantage no smaller competitor can match without similar capital deployment.
Joint Commission and ACHC accreditation, Medicare provider status, state pharmacy licensure across multiple states — these are 3–5 year head starts a new entrant cannot compress.
Medicare can change ASP+6% drug reimbursement methodology. Mitigation: diversify payer mix early, build commercial payer concentration above 50%, monitor MedPAC recommendations quarterly.
One serious infusion reaction with a poor outcome can trigger regulatory scrutiny, lawsuits, and reputational damage. Mitigation: rigorous protocols, MD on-site at every infusion, robust adverse event reporting, $10M+ professional liability per center.
The 2024 Baxter IV bag disruption showed how vulnerable infusion operations are. Mitigation: diversified supplier relationships, 90-day inventory buffer on critical supplies, secondary distributor relationships.
Establishing in-network status with major payers can take 12–18 months. Mitigation: begin contracting before opening Center 1, hire dedicated payer relations leader by Month 6.
Strong medical directors are rare and expensive. A single departure can destabilize a center. Mitigation: equity participation, regional medical leadership structure, redundancy planning.
Option Care, CVS, and Walgreens could imitate the software-led approach. Mitigation: move faster, use AI-native architecture they cannot retrofit, lock in software customers before incumbents recognize the threat.
This entire trajectory rests on the next 90 days of execution. Most billion-dollar companies fail not on strategy but on the first quarter of execution. These are the only actions that matter.
Engage healthcare attorney specializing in infusion businesses. Form the PLLC or MSO structure per state requirements. Identify and recruit a board-certified Medical Director willing to anchor the launch. Begin Medicare provider enrollment (CMS-855 takes 60–90 days). File for state pharmacy licensure if doing in-house compounding.
Identify launch metro and target Class A medical office space (1,800–2,500 sq ft). Sign LOI. Begin Joint Commission or ACHC accreditation paperwork. Open business bank accounts and establish credit facility relationships with healthcare-focused banks (Live Oak, First Citizens healthcare group, Truist healthcare).
Hire Director of Operations (preferably with prior infusion center experience), Director of Revenue Cycle, and lead engineer for AI prior auth product. Engage payer contracting consultant to initiate BCBS, UnitedHealthcare, Aetna contracts. Build a simple v0 of the prior auth automation tool using current LLM stack.
Director of Operations begins systematic outreach to 30 referring specialists in launch metro. Center build-out begins. Initiate Series Seed raise of $4–6M from healthcare-focused funds (7wireVentures, Optum Ventures, Bessemer Healthcare). Soft launch with first 10 patients via friendly specialist relationships in Month 4.
These 12 actions, executed in order, take the company from a strategic memo to an operating business with patients receiving care, software in beta, and capital committed. Everything beyond Day 90 is iteration on a foundation that already exists. Most founders skip steps in this sequence and pay for it for years.
$1B companies are not built on better ideas. They are built on better sequencing of mediocre ideas executed without flinching. The strategy in this memo is sufficient — the question is whether the first 90 days are run with the discipline they require.